Validation of the DECA criteria for allergic conjunctivitis severity and control

Sánchez-Hernández, M. Cesárea ; Navarro, Ana M. ; Colás, Carlos (Universidad de Zaragoza) ; Cuvillo, Alfonso del ; Sastre, Joaquín ; Mullol, Joaquim ; Valero, Antonio

Resumen: Background: Allergic conjunctivitis (AC) is usually associated to allergic rhinitis (AR), but the severity and control of ocular symptoms should be assessed independently to improve diagnosis and treatment. The criteria from the Spanish consensus document on allergic conjunctivitis (DECA) aimed to be used as a patient-reported instrument for AC management. Here we validate these criteria for classifying AC severity and defining its control following COSMIN guidelines recommendations. Methods: Patients with moderate or severe AR [reflective total nasal symptom score (rTNSS) score ≥ 8] and concomitant AC were recruited from hospitals in Spain. Patients were classified according to the severity of ocular symptoms as mild, moderate, or severe, and classified with respect to control as controlled and non-controlled, using the DECA criteria. To validate these criteria, comparisons with the validated modified allergic rhinitis and its impact on asthma (mARIA), reflective total ocular symptom score (rTOSS), rhinitis control assessment test (RCAT), ESPRINT-15 questionnaires, a conjunctival hyperemia scale and a visual analogue scale (VAS) for ocular symptoms were performed. Results: A total of 128 patients participated in the validation. Mean age was 34.4 ± 12.1 years; 72.7% were women. The DECA criteria showed a good discriminant validity, reflecting a high capacity to differentiate between mild, moderate, and severe patients, and controlled from uncontrolled patients. A strong association between AC and AR was reflected in the comparison between the DECA and the mARIA criteria (p < 0.0001). The DECA criteria for severity and control presented satisfactory properties for longitudinal validity and responsiveness. Conclusions: Validation of the DECA criteria for severity and control of AC suggested that it can be useful in the evaluation of eye symptoms and follow-up of therapies.

Idioma: Inglés

DOI: 10.1186/s13601-020-00349-4

Año: 2020

Publicado en: Clinical and translational allergy 10, 1 (2020), [9 pp.]
ISSN: 2045-7022

Factor impacto JCR: 5.871 (2020)

Categ. JCR: ALLERGY rank: 8 / 28 = 0.286 (2020) - Q2 - T1

Factor impacto SCIMAGO: 0.978 - Immunology (Q2) - Pulmonary and Respiratory Medicine (Q2) - Immunology and Allergy (Q2)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)